<?xml version="1.0" encoding="UTF-8"?>
<p>The historical use of (hydroxy)chloroquine in antimalarial treatment, but also in connective tissue diseases, has resulted in a well‐documented safety and tolerance profile in pregnant women.
 <xref rid="bjo16270-bib-0028" ref-type="ref">
  <sup>28</sup>
 </xref> Animal studies undertaken during the Zika virus epidemic, have also suggested that chloroquine may also reduce the risk of viral transplacental transmission to the fetus.
 <xref rid="bjo16270-bib-0029" ref-type="ref">
  <sup>29</sup>
 </xref> The optimal dosage to be used in pregnant women will have to be specified, but it appears that there is no pharmacokinetic difference between chloroquine and its major metabolite between pregnant and non‐pregnant women,
 <xref rid="bjo16270-bib-0030" ref-type="ref">
  <sup>30</sup>
 </xref> meaning standard, non‐pregnant doses could be unaltered.
</p>
